Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18086456 | 0.88 | NPC1 (0.56) | SMN1; SMN2POLBALDH1A1CA2HPGD | |
| SCHEMBL4257896 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2POLBALDH1A1MAPTCA2 | |
| SCHEMBL30905400 | 0.88 | POLB (0.67) | POLBALDH1A1MAPTCA2CA12 | |
| SCHEMBL22938995 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2POLBALDH1A1MAPTCA2 | |
| SCHEMBL22939048 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2POLBALDH1A1MAPTCA2 | |
| SCHEMBL22939676 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2POLBALDH1A1MAPTCA2 | |
| SCHEMBL22939679 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2POLBALDH1A1MAPTCA2 | |
| SCHEMBL29780254 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2POLBALDH1A1MAPTCA2 | |
| SCHEMBL21113585 | 0.86 | SMN1; SMN2 (0.72) | SMN1; SMN2POLBALDH1A1HPGDNPC1 | |
| SCHEMBL16103590 | 0.86 | CA2 (0.45) | SMN1; SMN2POLBALDH1A1MAPTCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| EP-1819671-A2 | HCV INHIBITORS WITH CARBAZOLE STRUCTURE | SmithKline Beecham Corporation (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006118607-A2 | HCV INHIBITORS WITH CARBAZOLE STRUCTURE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170906-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | SMN1; SMN2 4443/4885POLB 3538/4885ALDH1A1 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.